FirstWord

The "durable" overall survival results for Namodenoson in patients with advanced pancreatic ductal adenocarcinoma sent the firm's shares up more than 40%.

Acquisition adds to Ipsen's rare disease pipeline a late-stage antibody programme targeting BK polyomavirus in kidney transplant recipients.

Tregzi was approved for haematopoietic and immunologic reconstitution in patients receiving a stem cell transplantation, and to improve chronic graft-versus-host disease-free survival.

At an event on Tuesday, the AI heavyweight said it plans to target "neglected" diseases.

Vijay Kumar is exiting his post as acting director of the Office of Therapeutic Products within the agency's Center for Biologics Evaluation and Research.

Novel data support the use of liquid biopsy to guide cetuximab rechallenge in metastatic colorectal cancer1 Jul 2026Colon and Rectal Cancer ESMO Gastrointestinal Cancers Congress 2026Tumours with no c...

Advanced analytical methods integrating clinical trial and real-world data address key evidence gaps in rare, difficult-to-treat blood cancers Across both studies, mogamulizumab was associated with i...

Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104Greater improvements observed in children wit...

Company remains sharply focused on its ongoing global development program for crofelemer for rare IF diseasesNear-term milestones for IF program buttressed by continuing groundbreaking results of stud...

SOLANA BEACH, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop trea...